Today: 9 May 2026
Babcock share price today: BAB slips after fresh buyback filing, March year-end in focus
29 January 2026
2 mins read

Babcock share price today: BAB slips after fresh buyback filing, March year-end in focus

London, Jan 29, 2026, 09:29 GMT — Regular session

  • Babcock shares edged down in early London trading after the company disclosed a new buyback program
  • The company revealed a small buyback of its treasury shares. At the same time, a separate filing showed an executive selling stock after an award vested.
  • Investors are zeroing in on the pace of buybacks as the group nears its March year-end and gears up for the upcoming earnings reports

Babcock International Group (BAB.L) shares slipped 0.3% to 1,484 pence by 0929 GMT on Thursday after unveiling another share buyback. The defence services firm’s stock closed at 1,489 pence on Wednesday and traded in a range from 1,476 to 1,500 pence earlier in the session.

The filing arrives with the stock lingering near its 52-week high, a level where traders keep a sharp eye on any changes in share count. Buybacks nibble away at the float steadily, day after day.

Babcock’s latest trading update shows it has returned £90 million out of a £200 million buyback programme started in Q2, with plans to complete the repurchase by the March year-end. The company is nearing the close of its financial year ending March 31, 2026. This update offers investors a concise view of cash flow and how much remains for share buybacks.

Babcock revealed in a regulatory filing on Thursday that it acquired 6,657 shares on Jan. 28 through J.P. Morgan Securities, paying an average price of 1,502.3523 pence each. The shares traded between 1,485 and 1,517 pence during the purchase. Instead of cancelling them, the company will hold these shares in treasury. This latest buy raises the total repurchased since July 24 to 7.94 million shares, at a cost of £88.6 million.

A separate filing showed Chief People Officer Louise Atkinson exercised a nil-cost share award before selling 24,749 shares at £14.85 apiece on Jan. 27. The sale brought in £367,522.65, the notice stated.

Buybacks and executive sales often appear side by side in headlines, yet they’re quite distinct. Buybacks happen when a company buys back its own shares to hold in its treasury. Executive sales, on the other hand, involve insiders selling shares they received through awards to cash out.

Babcock works within the UK defence supply chain alongside firms like BAE Systems and QinetiQ, relying heavily on long-term government contracts for much of its revenue. In this environment, short-term shifts in share count tend to get lost amid rapid swings in sector sentiment.

Buybacks may still move the needle, even if just slightly. The average price paid on Wednesday outpaced Thursday’s trading price, a gap that might draw quick attention to whether the programme is tightening up on price as shares hover near recent highs.

Buybacks can stop suddenly during blackout windows or if cash runs low, and Babcock’s earnings still depend heavily on delivery targets and government spending decisions. Any slowdown in key projects or a snag in working capital might quickly overshadow the ongoing share repurchases.

Look for more buyback announcements soon, along with updates on how quickly the group plans to complete the program by its March year-end.

Babcock’s investor calendar shows its latest update came with the third-quarter trading statement on Jan. 23. No new reporting dates have been announced since. Investors are now waiting for a date on the annual results for the year ending March 31, 2026.

Stock Market Today

  • AbbVie Stock Evaluation: Undervalued After Recent Pullback or Overpriced?
    May 9, 2026, 10:02 AM EDT. AbbVie's shares fell 4.1% over the past week, trading near $202, yet posting strong returns of 12.8% over one year and nearly 110% over five years. Using a Discounted Cash Flow (DCF) model, Simply Wall St estimates AbbVie's intrinsic value at about $418.78 per share, implying the stock is undervalued by 51.6%. The DCF projects free cash flow growth from $18 billion to $34.3 billion by 2030. However, valuation scores are mixed, with 3 out of 6 points indicating some caution, reflecting investor reassessment amid shifts in healthcare and AI sector opportunities. AbbVie's peers have outperformed it recently, raising questions about its relative appeal. Investors should weigh these factors when considering an entry point for this large-cap pharmaceutical firm.

Latest article

Micron Stock Rally: AI Memory Shortage Sends Market Value Past $850 Billion

Micron Stock Rally: AI Memory Shortage Sends Market Value Past $850 Billion

9 May 2026
Micron Technology jumped over 15% Friday to $746.81, pushing its market value near $853 billion, as investors bet on soaring AI data center demand. The company reported fiscal Q2 revenue nearly tripled to $23.86 billion and net income of $13.79 billion. Micron forecast Q3 revenue of $33.5 billion and expects 2026 capital spending above $25 billion. Sandisk also rose more than 16% on similar demand.
BP share price climbs in London as oil firms on Iran worries; buyback and Venezuela gas in focus
Previous Story

BP share price climbs in London as oil firms on Iran worries; buyback and Venezuela gas in focus

Aviva share price climbs as gilt yields hit a two-month high — what to watch before March results
Next Story

Aviva share price climbs as gilt yields hit a two-month high — what to watch before March results

Go toTop